Plain-English translation of NCT06361316 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether combined with two other chemotherapy drugs (oxaliplatin and tegafur) can help prevent pancreatic cancer from coming back after surgery. The study wants to see how well this three-drug combination works and whether it is safe for people who have had their pancreatic cancer surgically removed. This is called adjuvant chemotherapy—treatment given after surgery to reduce the chance of the cancer returning.
Pancreatic cancer is a serious disease, and even after surgery removes the visible tumor, cancer cells can sometimes remain in the body and cause the disease to return. Researchers are testing this new medication combination to see if it can improve survival rates and reduce the risk of cancer recurrence better than current treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination through intravenous infusions and by mouth over 6 treatment cycles, with each cycle lasting 30 days. Every 15 days, you would come in for an infusion of two of the medications, while taking the third medication as a pill at home for 10 days per cycle. The treatment is designed to last approximately 6 months, and you would likely have regular check-ins to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
Kuirong Jiang
Collaborators
CSPC Ouyi Pharmaceutical Co., Ltd.
Enrollment target
~53 participants
Started
April 2024
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
KuiRong Jiang, archiater
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.